Detalhe da pesquisa
1.
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
Lancet Oncol
; 24(8): 881-891, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37451291
2.
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 380(12): 1116-1127, 2019 03 21.
Artigo
Inglês
| MEDLINE | ID: mdl-30779529
3.
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 21(12): 1563-1573, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-33284113
4.
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.
Clin Infect Dis
; 70(9): 1799-1808, 2020 04 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31400759
5.
Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial.
Clin Infect Dis
; 69(12): 2045-2056, 2019 11 27.
Artigo
Inglês
| MEDLINE | ID: mdl-30861061
6.
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
JAMA
; 319(8): 788-799, 2018 02 27.
Artigo
Inglês
| MEDLINE | ID: mdl-29486041
7.
The role of lead in the etiopathogenesis of male fertility reduction.
Wiad Lek
; 71(6): 1155-1160, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-30267492
8.
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Lancet Oncol
; 14(13): 1287-94, 2013 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-24206640
9.
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
Eur Urol
; 84(5): 449-454, 2023 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37500340
10.
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
Eur Urol
; 82(4): 427-439, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35843776
11.
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454].
Eur Urol
; 85(2): e58-e59, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38071169
12.
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur. Urol. (2023)].
Eur Urol
; 84(5): e123-e124, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37666734
13.
Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial.
Clin Genitourin Cancer
; 15(1): 72-76, 2017 02.
Artigo
Inglês
| MEDLINE | ID: mdl-27498023